Fulcrum Therapeutics (FULC) News Today $3.46 -5.39 (-60.90%) (As of 03:08 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 12 at 2:03 PM | reuters.comFulcrum's muscle disorder drug fails in late-stage studySeptember 12 at 2:03 PM | tmcnet.comFULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law FirmSeptember 12 at 2:03 PM | finance.yahoo.comFulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key testSeptember 12 at 2:03 PM | finance.yahoo.comFulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal TrialSeptember 12 at 1:35 PM | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Earns Market Perform Rating from Leerink PartnersLeerink Partners reiterated a "market perform" rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday.September 12 at 11:14 AM | marketbeat.comBank of America Lowers Fulcrum Therapeutics (NASDAQ:FULC) to UnderperformBank of America cut Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and dropped their price target for the company from $10.00 to $2.00 in a research note on Thursday.September 12 at 9:01 AM | reuters.comFulcrum Therapeutics IncSeptember 12 at 9:01 AM | msn.comFulcrum stock slumps after muscle disorder drug fails in late-stage studySeptember 12 at 9:01 AM | marketwatch.comFulcrum Therapeutics Shares Sink After Losmapimod Trial Misses EndpointSeptember 12 at 9:01 AM | msn.comFulcrum crashes as GSK-partnered lead program failsSeptember 12 at 6:55 AM | globenewswire.comFulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)September 11 at 12:52 PM | msn.comB of A Securities Upgrades Fulcrum Therapeutics (FULC)September 11 at 3:39 AM | americanbankingnews.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded by Bank of America to "Neutral"September 9 at 2:28 PM | benzinga.comFulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle DiseaseSeptember 9 at 12:26 PM | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up to $8.54Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up to $8.54September 9 at 7:48 AM | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded to "Neutral" by Bank of AmericaBank of America raised shares of Fulcrum Therapeutics from an "underperform" rating to a "neutral" rating and raised their price objective for the company from $5.00 to $10.00 in a research note on Monday.September 9 at 2:07 AM | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $16.33 Average Price Target from BrokeragesSeptember 9 at 1:33 AM | americanbankingnews.comFinancial Survey: Fulcrum Therapeutics (NASDAQ:FULC) & Eton Pharmaceuticals (NASDAQ:ETON)September 6, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Buy" from AnalystsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been given an average rating of "Buy" by the six analysts that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price objective amongSeptember 4, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Up 5.2%Fulcrum Therapeutics (NASDAQ:FULC) Trading Up 5.2%September 2, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Large Growth in Short InterestFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 8,150,000 shares, a growth of 6.1% from the July 31st total of 7,680,000 shares. Based on an average daily trading volume, of 901,700 shares, the days-to-cover ratio is presently 9.0 days.August 28, 2024 | finance.yahoo.comOne Fulcrum Therapeutics Insider Raised Their Stake In The Previous YearAugust 27, 2024 | entrepreneur.com3 High-Potential Biotech Stocks Under $10August 27, 2024 | globenewswire.comFulcrum Therapeutics to Participate in Upcoming September ConferencesAugust 27, 2024 | marketbeat.comFulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw some unusual options trading on Tuesday. Stock traders acquired 4,020 put options on the stock. This represents an increase of approximately 205% compared to the typical daily volume of 1,320 put options.August 27, 2024 | forbes.comScaling Up Without Selling Out: How Biotechs Can Preserve Culture During CommercializationAugust 26, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7%Fulcrum Therapeutics (NASDAQ:FULC) Trading Up 7%August 23, 2024 | bizjournals.comThe Petri Dish: Abata lands big pharma funds; Broad’s new partnerAugust 23, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 22, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3%Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.3%August 20, 2024 | marketbeat.comAssenagon Asset Management S.A. Purchases New Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Assenagon Asset Management S.A. purchased a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 497,456 shares of the company's stoAugust 19, 2024 | globenewswire.comFulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance OfficerAugust 18, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Up 5.8% in JulyFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw a large increase in short interest in July. As of July 31st, there was short interest totalling 7,680,000 shares, an increase of 5.8% from the July 15th total of 7,260,000 shares. Based on an average trading volume of 873,100 shares, the days-to-cover ratio is currently 8.8 days.August 15, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Up 8.8%Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 8.8%August 14, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.5%Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.5%August 13, 2024 | finance.yahoo.comAtavistik Bio Strengthens Leadership Team with Appointment of Paul Bruno, Ph.D. as Chief Business OfficerAugust 12, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Buy" from BrokeragesShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have been given a consensus rating of "Buy" by the seven research firms that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1-year price target amongAugust 9, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Position Boosted by Jane Street Group LLCJane Street Group LLC boosted its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 54.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 535,062 shares of the company's stock after buyAugust 8, 2024 | investing.comFulcrum Therapeutics (FULC) Earnings Dates & ReportsAugust 6, 2024 | barrons.comFulcrum Therapeutics Inc.August 5, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 10.8%Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 10.8%August 4, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 101,658 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Jacobs Levy Equity Management Inc. trimmed its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 83.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,472 shares of the company's stockAugust 2, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Fulcrum Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Investment analysts at Leerink Partnrs issued their FY2026 earnings estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Wednesday, July 31st. Leerink Partnrs analyst J. Schwartz expects that the companAugust 1, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $17.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday.July 31, 2024 | finance.yahoo.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024July 31, 2024 | globenewswire.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024July 30, 2024 | markets.businessinsider.comFulcrum Therapeutics earnings: here's what Wall Street expectsJuly 30, 2024 | msn.comFulcrum Therapeutics Q2 2024 Earnings PreviewJuly 30, 2024 | bizjournals.comFulcrum Lifting opens first branch in Columbus Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Trader Books $13M Profit on “Nvidia of Crypto” (Ad)A position trader recently booked an estimated $13.2 million profit on a single crypto currency… This little-known coin, dubbed the "Nvidia of crypto," is fueling the artificial intelligence boom – allowing top companies to train their AI systems without the need for expensive microchips. Click here to review my research and the strategy I've developed for the opportunity to trade this c FULC Media Mentions By Week FULC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼0.740.79▲Average Medical News Sentiment FULC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼113▲FULC Articles Average Week Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SGMO News Today BLUE News Today KZR News Today VERA News Today HRMY News Today ZLAB News Today MIRM News Today NTLA News Today KROS News Today AKRO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 9/12/2024 by MarketBeat.com Staff From Our PartnersRecently listed NASDAQ firm is well positioned for growth with game-changing AI platform for e-commerce.With an innovative AI platform, one tiny but growing NASDAQ firm is ushering in a new e-commerce era and is tr...Smallcaps Daily | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredTesla of the Skies?Remember when Tesla disrupted the auto industry? Buckle up, because they could have the potential to do the sa...Market JAR | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FULC Stock Alerts